Literature DB >> 3079654

Serum bone GLA-protein is not a sensitive marker of bone turnover in Paget's disease of bone.

P D Delmas, B Demiaux, L Malaval, M C Chapuy, P J Meunier.   

Abstract

Serum bone Gla-protein (sBGP) was measured in 32 patients with untreated Paget's disease of bone. Despite clinical and biological symptoms of active disease in all patients, sBGP was normal in 13/32 patients (41%). There was a striking discrepancy between the moderate increase of sBGP above normal values (11.4 +/- 4.5 vs 6.0 +/- 2.1 ng/ml) and the marked increase of both serum alkaline phosphatase (sAP) and urinary hydroxyproline (uOHP). sBGP was weakly correlated with sAP (r = 0.50, p less than 0.01), uOHP (r = 0.48, p less than 0.01) and with the extension of the disease (r = 0.48, p less than 0.01). We conclude that sBGP is not a sensitive marker of bone turnover in patients with Paget's disease of bone, and should be interpreted with caution in this condition.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3079654     DOI: 10.1007/bf02556596

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  10 in total

1.  Effects of warfarin on bone. Studies on the vitamin K-dependent protein of rat bone.

Authors:  P A Price; M K Williamson
Journal:  J Biol Chem       Date:  1981-12-25       Impact factor: 5.157

2.  Bone histomorphometry in Paget's disease. Quantitative and dynamic analysis of pagetic and nonpagetic bone tissue.

Authors:  P J Meunier; J M Coindre; C M Edouard; M E Arlot
Journal:  Arthritis Rheum       Date:  1980-10

3.  [Analysis of disorders of the principal pathways of calcium metabolism in Paget's disease. Effects of calcitonin administration. 26 cases].

Authors:  G Coutris; J Cayla; J Rondier; J N Talbot; J P Bonvarlet; G Milhaud
Journal:  Rev Rhum Mal Osteoartic       Date:  1975-12

4.  Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis.

Authors:  J P Brown; P D Delmas; L Malaval; C Edouard; M C Chapuy; P J Meunier
Journal:  Lancet       Date:  1984-05-19       Impact factor: 79.321

5.  Urinary gamma-carboxyglutamic acid and serum osteocalcin as bone markers: studies in osteoporosis and Paget's disease.

Authors:  C M Gundberg; J B Lian; P M Gallop; J J Steinberg
Journal:  J Clin Endocrinol Metab       Date:  1983-12       Impact factor: 5.958

6.  Assessment of bone turnover in postmenopausal osteoporosis by measurement of serum bone Gla-protein.

Authors:  P D Delmas; H W Wahner; K G Mann; B L Riggs
Journal:  J Lab Clin Med       Date:  1983-10

7.  New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone GLA protein in the plasma of normal subjects and patients with bone disease.

Authors:  P A Price; J G Parthemore; L J Deftos
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

8.  Turnover rate of skeletal alkaline phosphatase in humans.

Authors:  S Posen; H S Grunstein
Journal:  Clin Chem       Date:  1982-01       Impact factor: 8.327

9.  Changes in plasma bone GLA protein during treatment of bone disease.

Authors:  L J Deftos; J G Parthemore; P A Price
Journal:  Calcif Tissue Int       Date:  1982-03       Impact factor: 4.333

10.  Increase in serum bone gamma-carboxyglutamic acid protein with aging in women. Implications for the mechanism of age-related bone loss.

Authors:  P D Delmas; D Stenner; H W Wahner; K G Mann; B L Riggs
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

  10 in total
  10 in total

Review 1.  Treatment of patients with Paget's disease of bone.

Authors:  C Roux; M Dougados
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

2.  Clinical value of the measurement of bone remodelling markers in primary hyperparathyroidism.

Authors:  S Minisola; L Scarnecchia; V Carnevale; F Bigi; E Romagnoli; M T Pacitti; R Rosso; G F Mazzuoli
Journal:  J Endocrinol Invest       Date:  1989-09       Impact factor: 4.256

Review 3.  Paget's disease of bone: diagnosis and management.

Authors:  D Hosking; P J Meunier; J D Ringe; J Y Reginster; C Gennari
Journal:  BMJ       Date:  1996-02-24

Review 4.  Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  A Fitton; D McTavish
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

Review 5.  Emerging strategies and therapies for treatment of Paget's disease of bone.

Authors:  Laëtitia Michou; Jacques P Brown
Journal:  Drug Des Devel Ther       Date:  2011-04-26       Impact factor: 4.162

6.  Risk of osteoporosis in men with chronic bronchitis.

Authors:  J P Praet; A Peretz; S Rozenberg; J P Famaey; P Bourdoux
Journal:  Osteoporos Int       Date:  1992-09       Impact factor: 4.507

7.  Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate.

Authors:  C de la Piedra; A Rapado; E M Díaz Diego; M A Díaz Martín; C Aguirre; E López Gavilanes; M Díaz Curiel
Journal:  Calcif Tissue Int       Date:  1996-08       Impact factor: 4.333

8.  Correlation among plasma osteocalcin, growth hormone, and somatomedin C in acromegaly.

Authors:  C de la Piedra; J Larrañaga; N Castro; C Horcajada; A Rapado; J L Herrera Pombo; E Carbó
Journal:  Calcif Tissue Int       Date:  1988-07       Impact factor: 4.333

9.  beta 2-Microglobulin in Paget's bone disease.

Authors:  H Rico; E Ripoll; I Arribas; M Revilla; P Relea; L F Villa; M A de Buergo
Journal:  Calcif Tissue Int       Date:  1994-05       Impact factor: 4.333

10.  Markers of bone turnover for the management of patients with bone metastases from prostate cancer.

Authors:  P Garnero; N Buchs; J Zekri; R Rizzoli; R E Coleman; P D Delmas
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.